Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCB | Brussels | Healthcare | Pharmaceuticals | €31.28B | 130.9x | -4.78 | €164.95 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
Tubize-Fin | Brussels | Healthcare | Pharmaceuticals | €5.68B | 64.6x | €127.80 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.3% Upside | Upgrade to Pro+ | ||
Fagron | Brussels | Healthcare | Pharmaceuticals | €1.32B | 17.1x | 1.13 | €18.12 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.4% Upside | Upgrade to Pro+ | |
Hyloris | Brussels | Healthcare | Pharmaceuticals | €92.40M | -13x | 2.18 | €3.85 | 16.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biosenic | Brussels | Healthcare | Pharmaceuticals | €1.59M | -0.1x | -0 | €0.006 | 13.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |